Recombinant vWF concentrate for bleeding on ECMO
Part of Blood & lymphatic, Heart & circulation clinical trials.
This trial tests whether a medication called recombinant von Willebrand factor (vWF) can help control major bleeding in adults who are on life support with ECMO. If you are on ECMO and have a serious bleed, this treatment might help stop the bleeding.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are currently on ECMO (a machine that helps your heart and lungs work).
- You have a major bleeding event rated grade 3 or higher by your doctor.
- You have been off blood thinners (anticoagulation) for at least 4 hours.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests vonicog alfa (an rVWF treatment) to prevent and control bleeding in children with severe von Willebrand disease (vWD). You may be able to join if your child has severe vWD and has been on prior clotting factor treatment with ongoing bleeding despite that care.
This trial studies whether people on a breathing machine called VV-ECMO can be managed without routine blood thinners, to reduce bleeding risk. It is meant for adults with severe lung failure (ARDS) and checks that it is safe for you to avoid anticoagulation.
This trial is for adults in the ICU who recently started ECMO (a heart-lung bypass machine). It tests whether a blood test called D-dimer can help predict bleeding risk, which might improve safety for people on ECMO.
This trial tests whether a special algorithm can reduce repeat bleeding from the gut or nose in people with inherited Von Willebrand disease. If you have had serious nosebleeds or digestive bleeding, this study may help find a better way to manage your condition.
This trial tests if bivalirudin is a safe and effective blood thinner for people on ECMO, a machine that helps your heart and lungs. You may be eligible if you need this therapy and have no past reactions to similar medicines.
This trial tests a new drug called VGA039 that is injected under the skin to prevent bleeding episodes in people with von Willebrand disease. It is for those who bleed frequently and are not currently using regular preventive treatments.
Hear when a new Bleeding Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.